Maze Therapeutics (MAZE) Enterprise Value (2025 - 2026)

Maze Therapeutics has reported Enterprise Value for 3 years, with the latest figure at -$352.4 million in Q1 2026.

• Quarterly Enterprise Value fell 19.71% year-over-year to -$352.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$352.4 million (down 19.71% YoY) and the FY2025 annual result came in at -$341.9 million, down 73.73% from the prior year.
• Enterprise Value slipped to -$352.4 million in Q1 2026 per MAZE's latest filing, from -$341.9 million in the prior quarter.
• Over five years, Enterprise Value peaked at -$30.0 million in Q1 2024 and troughed at -$383.9 million in Q3 2025.
• A 3-year average of -$243.2 million and a median of -$264.5 million in 2025 frame the typical range for Enterprise Value.
• The sharpest annual moves came in 2025 and 2026: Enterprise Value slumped 880.49% in 2025, then slipped 19.71% in 2026.
• Over 3 years, Enterprise Value stood at -$196.8 million in 2024, then plunged by 73.73% to -$341.9 million in 2025, then retreated by 3.06% to -$352.4 million in 2026.
• According to Business Quant data, Enterprise Value over the past three periods registered -$352.4 million, -$341.9 million, and -$383.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.